Aslan Gets Singapore Nod For Initial Trial Of RA Candidate From Spain’s Almirall
This article was originally published in PharmAsia News
Executive Summary
Aslan Pharmaceuticals received approval for a Phase I clinical trial of a rheumatoid arthritis DHODH inhibitor by Singapore’s Health Sciences Authority and will work with CRO Quintiles at Changi General Hospital.